Skip to content
Global oncology company BeiGene on July 23 announced the opening of its new flagship U.S. facility in Hopewell, NJ, at the Princeton West Innovation Campus.
The 42-acre facility cost $800 million and is the culmination of a three-year project, according to a statement from the company. With an interior space reported at 400,000 square feet, it is designed to house integrated manufacturing and research and development facilities.
BeiGene, a member of the Biotechnology Innovation Organization (BIO), boasts more than 30 molecules at clinical or commercial stage. The company’s drug development focuses on solid tumor and hematology drugs.
“We are pursuing a broad and deep pipeline with the potential to address 80 percent of the world’s cancers by incidence. In addition to leveraging our internal research resources, we continually evaluate external early-stage assets that might enhance our pipeline and opportunities,” BeiGene says.
The new facility will allow further development for the growing company, according to John V. Oyler, Co-Founder, Chairman and CEO of BeiGene.
“BeiGene has experienced unprecedented global growth, and the addition of our facility at the Princeton West Innovation Campus adds manufacturing and clinical development capabilities that will further strengthen our differentiated strategy which leverages speed, efficiency and technology to advance quality medicines faster for patients,” said Oyler.
A leading region for biotech
“We are proud to be a part of New Jersey’s biopharmaceutical community that is rich in research and development and manufacturing talent,” Oyler continued.
The new facility is close to Princeton University and not far from the life-sciences cluster in New Brunswick, NJ. The Trenton-Princeton region boasted 3,701 jobs in drugs and pharmaceuticals in 2021, according to a TEConomy report commissioned by BIO and the Council of State Bioscience Associations (CSBA).
BeiGene’s facility will add to the job count, with “hundreds of skilled high-tech jobs at the site by the end of 2025,” according to the company. “New Jersey is a global leader in biopharmaceutical manufacturing and R&D with nine of the top 10 R&D companies in the world having a presence in the state.”
About 250 people attended the grand opening ceremony, including state and local officials, as well as Debbie Hart, CEO of BioNJ.
Image: BeiGene’s flagship biologics manufacturing facility and clinical R&D center at the Princeton West Innovation Campus in Hopewell, N.J. (Photo Courtesey BeiGene)
